Enveric Biosciences (STU:SLZ0) General and Admin. Expense: €4.88 Mil (TTM As of Mar. 2026)


STU:SLZ0 Enveric Biosciences Inc STU:SLZ0
30 GF Score
Price €55.89
! 1 Warning Sign
View Full Analysis

What is Enveric Biosciences General and Admin. Expense?

Enveric Biosciences STU:SLZ0 30 General and Admin. Expense is €4.88 Mil as of Mar. 2026. GuruFocus rates STU:SLZ0 with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Enveric Biosciences's General and Admin. Expense for the three months ended in Mar. 2026 was €1.08 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €4.88 Mil.

Enveric Biosciences General and Admin. Expense Related Terms

Enveric Biosciences General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Enveric Biosciences's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enveric Biosciences General and Admin. Expense Chart

Enveric Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.14 10.96 9.81 6.16 4.95

Enveric Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.26 1.06 1.22 1.52 1.08
STU:SLZ0
30GF Score
Enveric Biosciences Inc STU:SLZ0
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enveric Biosciences General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €4.88 Mil mean?
Enveric Biosciences (STU:SLZ0) has a General and Admin. Expense of €4.88 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Enveric Biosciences and its competitors.
Is Enveric Biosciences' General and Admin. Expense too high?
Enveric Biosciences' current General and Admin. Expense is €4.88 Mil. Overall, Enveric Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Enveric Biosciences' General and Admin. Expense compare to APVO and CNSP?
Enveric Biosciences' General and Admin. Expense of €4.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Enveric Biosciences and its competitors. Enveric Biosciences's current General and Admin. Expense is €4.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enveric Biosciences stock overvalued right now?
Enveric Biosciences (STU:SLZ0) has a current General and Admin. Expense of €4.88 Mil. The current General and Admin. Expense is €4.88 Mil. Enveric Biosciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Enveric Biosciences (STU:SLZ0), the current General and Admin. Expense is €4.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enveric Biosciences Business Description

Other Exchanges ENVB:USA
Address 245 First Street, 18th Floor, Riverview II, Cambridge, MA, USA, 02142
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
30GF Score

Get the complete analysis for STU:SLZ0

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€55.89
Price